Label: VITALIPID N- vitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione emulsion

  • NDC Code(s): 65219-335-10, 65219-335-82, 65219-337-10, 65219-337-62, view more
    65219-339-10, 65219-339-64
  • Packager: Fresenius Kabi USA, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Unapproved drug for use in drug shortage

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated September 7, 2023

If you are a consumer or patient please visit this version.

  • HEALTH CARE PROVIDER LETTER

    Figure

    Fresenius Kabi USA, LLC

    Three Corporate Drive
    Lake Zurich, Illinois 60047
    T 847-550-2300
    T 888-391-6300
    September 1, 2023 www.fresenius-kabi.us
    IMPORTANT PRESCRIBING INFORMATION
    Subject: Temporary importation of Vitalipid N ADULT and Vitalipid N INFANT to address drug shortage. The product is also labeled as Vitlipid N ADULT and Vitlipid N INFANT.

    Dear Healthcare Professional,

    Due to the critical shortage of parenteral multivitamins in the U.S. market, Fresenius Kabi USA, LLC (Fresenius Kabi USA) is coordinating with the U.S. Food and Drug Administration (FDA) to provide an alternative treatment option during this time. Fresenius Kabi USA has initiated temporary importation of Vitalipid Injection 10 mL Single Dose Glass Ampule into the U.S. market. The products imported into the U.S. may also be labeled with a slight variation of the proprietary name, Vitlipid N ADULT and Vitlipid N INFANT, depending on which country the product was originally intended. Other than the slight variation in the proprietary name, the products are identical, and the products will be referred to as Vitalipid N ADULT and Vitalipid N INFANT for the remainder of this letter. Vitalipid N ADULT and Vitalipid N INFANT are sterile oil-in-water emulsions containing fat-soluble vitamins in the oil phase. This product is marketed in Europe and is manufactured in the Fresenius Kabi Uppsala, Sweden plant.

    At this time, no other entity except Fresenius Kabi USA is authorized by the FDA to import or distribute Vitalipid Injection 10 mL Single Dose Glass Ampules (One Point Cut) in the U.S. The FDA has not approved Fresenius Kabi's Vitalipid product for marketing in the United States.

    This communication and product information is available on the Fresenius Kabi USA web site http://products.fresenius-kabi.us/product-323.html as well as on the FDA Drug Shortage web site. http://www.fda.gov/Drugs/DrugSafety/DrugShortages/default.htm.

    IMPORTANT DRUG INFORMATION

    It is important to note the following key differences between the Vitalipid and Infuvite:

    Product NameU.S. FDA-Approved Product (Infuvite Adult)1Imported Product (Vitalipid N Adult)2,3U.S. FDA-Approved Product (Infuvite Pediatric)4Imported Product (Vitalipid N Infant)5,6
    ManufacturerBaxter Fresenius Kabi Baxter Fresenius Kabi
    IndicationFor prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition Indicated in adult patients and children from 11 years of age as a supplement in intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A, D2, E and K1. For the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition Indicated in infants and children up to 11 years of age as a supplement in intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A, D2, E and K1.
    Product ingredients present13 vitamins present (water and fat soluble)
    Only 4 fat-soluble vitamins 13 vitamins present (water and fat soluble) Only 4 fat-soluble vitamins
    ContraindicationsExisting hypervitaminosis or history of hypersensitivity due to any vitamins or excipients contained in the formulation Egg, soy, peanut allergy, hypersensitivity to ingredient/excipient Existing hypervitaminosis or history of hypersensitivity due to any vitamins or excipients contained in the formulation Egg, soy, peanut allergy, hypersensitivity to ingredient/excipient
    StorageMinimize exposure to light because vitamins A, D and riboflavin are light sensitive. Store under refrigeration, 2-8°C (36-46°F). Between 2-25°C (36-77°F). Protect from light. Do not freeze Minimize exposure to light because vitamins A, D and riboflavin are light sensitive. Store under refrigeration, 2-8°C (36-46°F). Between 2-25°C (36-77°F). Protect from light. Do not freeze
    Bar code/NDC54643-5649-1 NDC (Finished Product): 6521933381; 6521933582
    NDC (Unit of Use): 6521933310; 6521933510
    54643-5646-1 NDC (Finished Product): 6521933762; 6521933964
    NDC (Unit of Use): 6521933710; 6521933910
    • Vitalipid is packaged in glass ampules, so filter needles must always be used in conjunction with a regular (nonfilter) needle during compounding to reduce the risk of introducing glass particles during administration
    • Vitalipid provides fat-soluble vitamins (A, D, E, K) only; Infuvite contains fat-soluble vitamins as well as 9 water-soluble vitamins (see Product Comparison Table below)
    • Vitalipid N ADULT and INFANT are contraindicated in patients with known hypersensitivity to any of the components (i.e., egg, soy, peanut protein, or any active substance or excipient)
    • Any barcodes on the Vitalipid N ADULT or Vitalipid N INFANT products will not be appropriately recognized by scanning systems used in the United States and should NOT be used. Institutions should manually input the product into their systems to confirm that barcode systems do not provide incorrect information when the product is scanned. Alternative procedures should be followed to assure that the correct drug product is being prepared and administered to individual patients.
    • Vitalipid N ADULT and Vitalipid N INFANT are available only by prescription in the U.S. However, the imported lots do not have the statement “Rx only” on their labeling.

    Effective immediately, and during this temporary period, Fresenius Kabi USA will offer the following presentation of adult and pediatric multivitamins:

    Product Description

    Vitalipid/Vitlipid N ADULT 10 mL2,3
    DescriptionConcentrated Emulsion for Injection
    Dosage Form:10 mL Single Dose Glass Ampule
    Package sizeBox contains 10 units of 10 mL
    Finished Product NDC6521933582
    Unit of Use NDC6521933510
    Lot Numbers/(Expiration Date)10SC1307/(2025.02.28); 10SD2190 (2025.03.31)
    VitaminActive Ingredients
    (per 1 mL)
    Active Ingredients
    (per 10 mL)
    Retinol palmitate (Vitamin A)99 mcg (330 IU)990 mcg (3300 IU)
    Ergocalciferol (Vitamin D2)0.5 mcg (20 IU)5 mcg (200 IU)
    All-rac-alpha-tocopherol (Vitamin E)0.91 mg (1IU)9.1 mg (10 IU)
    Phytomenadione (Vitamin K1)15 mcg150 mcg
    Excipients (per 1 mL)Excipients (per 10 mL)
    Purified egg phospholipids12 mg120 mg
    Glycerol anhydrous22 mg220 mg
    Purified soybean oil100 mg1000 mg
    Sodium hydroxideN/ATo pH 8
    Water for injectionN/ATo 1 mL
    Vitalipid/Vitlipid N INFANT 10 mL5,6
    DescriptionConcentrated Emulsion for Injection
    Dosage Form:Single Dose Glass Ampule
    Package Size:Box contains 10 units of 10 mL
    Finished Product NDC:6521933762; 6521933964
    Unit of Use NDC:6521933710; 6521933910
    Lot Numbers/(Expiration Date)10SB9030/(2025.01.31); 10SB9028/(2025.03.31)
    VitaminActive Ingredients
    (per 1 mL)
    Active Ingredients
    (per 10 mL)
    Retinol palmitate (Vitamin A)69 mcg (230 IU)690 mcg (2300 IU)
    Ergocalciferol (Vitamin D2)1 mcg (40 IU)10 mcg (400 IU)
    All-rac-alpha-tocopherol (Vitamin E)0.64 mg (0.7 IU)6.4 mg (7 IU)
    Phytomenadione (Vitamin K1)20 mcg200 mcg
    Excipients (per 1 mL)Excipients (per 10 mL)
    Purified egg phospholipids12 mg120 mg
    Glycerol anhydrous22 mg220 mg
    Purified soybean oil100 mg1000 mg
    Sodium hydroxideN/ATo pH 8
    Water for injectionN/ATo 1 mL

    Preparation/Administration

    • Vitalipid N ADULT must be diluted before use and strict aseptic technique must always be maintained during handling. Because Vitalipid N ADULT is packaged in a glass ampule, a filter needle must always be used in conjunction with a regular (nonfilter) needle during compounding to reduce the risk of introducing glass particulates during administration.
    • Both Vitalipid N ADULT and Vitalipid N INFANT are packaged in One Point Cut (OPC) ampules. OPC ampules are manufactured with a colored dot on the bulbous part of the ampule indicating the position where the ampule should be broken. Please follow the recommended instructions below to open the OPC ampule easily and safely:
      • Before an ampule is opened, any solution visible in the top portion (i.e., the head) should be moved to the bottom (i.e., body) by swirling the ampule in an upright position, tapping the ampule with one's finger, or inverting the ampule and then quickly swinging it into an upright position.
      • To open an ampule properly, the head should be cleansed with an alcohol swab. The alcohol swab can be left in place or a new alcohol-soaked gauze pad can be applied to prevent accidental cuts to the fingers as well as shattering of glass particles and aerosolized drug.
      • Pick up the ampule and hold its lower part (body) between your thumb and index finger and position the ampule so that the colored dot faces you.
      • Grasp the top of the ampule with your other hand. Place your thumb over the colored dot and index finger on the opposite side (back) of the bulbous part of the ampule.
      • Hold the bottom of the ampule firmly in an upright position and push away from oneself in a quick motion to “snap” open the ampule at the neck.
      • Ampules should NOT be opened toward the HEPA filter in the compounding work area (to prevent spraying of liquid) or toward other sterile preparation within the hood.
    • A regular needle should be used to withdraw 10 mL from one ampule. The regular needle should be removed from the syringe and replaced with a new filter needle to inject the 10 mL of Vitalipid into 500 mL of Intralipid (Fresenius Kabi). To ensure a homogeneous admixture, the bag should be inverted a couple of times immediately before the infusion. Vitalipid N ADULT is also used as a complement in parenteral nutrition (PN) formulations. Questions about compatibility may be directed to Fresenius Kabi USA, LLC Medical Affairs.
    • Vitalipid N ADULT should be added to an infusion within one hour of administration and the infusion should be completed within 24 hours from preparation to prevent microbiological contamination. Any remaining contents of opened ampules should be discarded.
    • Vitalipid N ADULT has been tested in PN formulations available outside of the U.S. containing lipid injectable emulsions under European standards and demonstrated compatibility with non-U.S. approved amino acids and other PN products. Branded U.S. PN products tested that have shown compatibility are SMOFlipid and Kabiven. Similar tests have not been conducted using U.S. amino acid products, thus caution should be taken when adding Vitalipid N ADULT to adult PN formulations. Vitalipid has also demonstrated compatibility when added to Kabiven in combination with some US amino acid branded products (e.g., Travasol 10% [Baxter Healthcare], Aminosyn II 15% [Hospira, Inc], Clinisol 15% [Baxter Healthcare], Prosol 20% [Baxter Healthcare]).
    • Vitalipid N INFANT must be diluted before use in Intralipid 20% (Fresenius Kabi). The daily dose must not exceed 10 mL. Because Vitalipid N INFANT is packaged in a glass ampule, a filter needle must always be used in conjunction with a regular (nonfilter) needle during compounding to reduce the risk of introducing glass particulates during administration. A regular needle should be used to withdraw up to 10 mL from 1 ampule. The regular needle should be removed from the syringe and replaced with a new filter needle to inject up to 10 mL of Vitalipid N INFANT into Intralipid 20% (Fresenius Kabi). To ensure a homogeneous admixture, the bag should be inverted a couple of times immediately before the infusion. After mixing by gentle agitation, the emulsion is infused as described for Intralipid (Fresenius Kabi). Any remaining contents of opened ampules should be discarded.
    • Vitalipid N INFANT has been tested in PN formulations available outside of the U.S. containing lipid injectable emulsions under European standards and demonstrated compatibility with non-U.S. approved pediatric amino acids and other PN products. Similar tests have not been conducted using U.S. amino acid products, thus caution should be taken when adding Vitalipid N INFANT to pediatric PN formulations. Branded U.S. PN products that have been tested and demonstrate compatibility include SMOFlipid, Intralipid (Fresenius Kabi).
    • Results from stability studies show that unopened ampules of Vitalipid N ADULT and Vitalipid N INFANT can be stored both at +5±3°C and at +25°C/60 % RH for 24 months. Based on available data, the product is proposed to be stored between 2°C – 25°C with a shelf life of 24 months. Do not freeze. Protect the product from light
    • Storage with dilution and admixture: The admixing of Vitalipid N ADULT and Vitalipid N INFANT in PN formulations has been investigated according to standard methods, documenting the physicochemical stability of admixtures after storage times up to 7 days. Vitalipid N ADULT and Vitalipid N INFANT have been tested with a variety of PN products marketed in the US, including Kabiven, PeriKabiven, and Intralipid 20% (Fresenius Kabi). The storage time and conditions specifically investigated compatibility of these products for 7 days, i.e., 6 days storage at 2°C -8°C followed by 24 hours at 20°C-25°C (i.e., 6+1 conditions). The methods employed are measurement of mean droplet size, droplet size distribution, pH, visual inspection and investigations aiming to determine precipitation in the aqueous phase. The latter have been carried out by comparisons with the corresponding aqueous systems without added lipid emulsion. The experimental results demonstrate that all tested compositions are stable and compatible under 6+1 conditions. It is important to note that there is variability in the U.S. use of different PN components which may not have been tested. If HCPs have specific questions based on their PN admixtures, the Fresenius Kabi Medical Information department can provide them with the information on the specific admixtures tested.
    • Consult Fresenius Kabi for further information on complete and balanced intravenous nutrition regimens.

    Product Comparison Table

    Product NameU.S. FDA-Approved Product (Infuvite Adult)1Imported Product (Vitalipid N Adult)2,3U.S. FDA-Approved Product (Infuvite Pediatric)4Imported Product (Vitalipid N Infant)5,6
    ManufacturerBaxter Fresenius Kabi Baxter Fresenius Kabi
    Multivitamins & active ingredient salt forms present13 vitamins present (water and fat soluble)

    These include:
    Thiamine (Vitamin B1)
    Riboflavin (Vitamin B2)
    Niacinamide (Vitamin B3)
    Dexpanthenol (Vitamin B5)
    Pyridoxine HCl (Vitamin B6)
    Biotin
    Folate
    Cyanocobalamin (Vitamin B12)
    Ascorbic acid (Vitamin C)
    Vitamin A (as palmitate)
    cholecalciferol (Vitamin D3)
    dl-Alpha-tocopherol acetate (Vitamin E)
    Vitamin K1
    Only fat-soluble vitamins


    These include:
    Retinol palmitate (vitamin A)
    Ergocalciferol (Vitamin D2)
    All-rac-Alpha-tocopherol (Vitamin E)
    Phytomenadione (Vitamin K1)
    13 vitamins present (water and fat soluble)

    These include:
    Thiamine (vitamin B1)
    Riboflavin (vitamin B2)
    Niacinamide (vitamin B3)
    Dexpanthenol (vitamin B5)
    Pyridoxine (vitamin B6)
    Biotin (B7)
    Folate (B9)
    Cyanocobalamin (B12)
    Ascorbic acid (Vitamin C)
    Vitamin A (as palmitate)
    cholecalciferol (Vitamin D3)
    dl-Alpha-tocopherol acetate (Vitamin E)
    Vitamin K1
    Only fat-soluble vitamins


    These include:
    Retinol palmitate (vitamin A)
    Ergocalciferol (Vitamin D2)
    All-rac-Alpha-tocopherol (Vitamin E)
    Phytomenadione (Vitamin K1)
    Differences in the amount of vitamins present in each 1 mLAscorbic acid: 20 mg
    Vitamin A: 330 IU
    Vitamin D3: 20 IU
    Thiamine (vitamin B1): 0.6 mg
    Riboflavin (Vitamin B2): 0.36 mg
    Pyridoxine (vitamin B6): 0.6 mg
    Niacinamide: 4 mg
    Dexpanthenol: 1.5 mg
    Vitamin E: 1 IU
    Vitamin K1: 15 mcg
    Folic Acid: 60 mcg
    Biotin: 6 mcg
    Vitamin B12: 0.5 mcg
    Ascorbic acid: 0
    Vitamin A: 330 IU
    Vitamin D2: 20 IU
    Thiamine: 0
    Riboflavin:0
    Pyridoxine: 0
    Niacinamide: 0
    Dexpanthenol: 0
    Vitamin E: 1 IU
    Vitamin K1: 15 mcg
    Folic Acid: 0
    Biotin: 0
    Vitamin B12: 0
    Ascorbic acid: 16 mg
    Vitamin A: 460 IU
    Vitamin D3: 80 IU
    Thiamine: 0.24 mg
    Riboflavin: 0.28 mg
    Pyridoxine: 0.2 mg
    Niacinamide: 3.4 mg
    Dexpanthenol: 1 mg
    Vitamin E: 1.4 IU
    Vitamin K1: 40 mcg
    Folic Acid: 28 mcg
    Biotin: 4 mcg
    Vitamin B12: 0.2 mcg
    Ascorbic acid: 0
    Vitamin A: 230 IU
    Vitamin D2: 40 IU
    Thiamine: 0
    Riboflavin: 0
    Pyridoxine: 0
    Niacinamide: 0
    Dexpanthenol: 0
    Vitamin E: 0.7 IU
    Vitamin K1: 20 mcg
    Folic Acid: 0
    Biotin: 0
    Vitamin B12: 0
    Package & Container SizeSingle dose Vial 1: 5 mL, Vial 2: 5 mL
    Pharmacy Bulk: Vial 1 – 50 mL,
    Vial 2 – 50 mL
    10 mL glass ampule, concentrated emulsion for injection Single dose: Vial 1: 5 mL, Vial 2: 5 mL
    Pharmacy Bulk: Vial 1 (40 mL Fill in 50 mL Vial) and Vial 2 (10 mL).
    10 mL glass ampule, concentrated emulsion for injection
    StorageMinimize exposure of INFUVITE ADULT to light because vitamins A, D and riboflavin are light sensitive.
    Store under refrigeration, 2-8°C (36-46°F).
    Between 2-25°C (36-77°F). Protect from light. Do not freeze Minimize exposure of INFUVITE PEDIATRIC to light because vitamins A, D and riboflavin are light sensitive. Store under refrigeration 2-8°C (36-46°F). Between 2- 25°C (36-77°F). Protect from light. Do not freeze
    Shelf LifeNot reported 24 months Not reported 24 months
    ExcipientsVial 1: polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, water for injection
    Vial 2: Propylene glycol, citric acid ± sodium citrate for pH, water for injection
    Soya oil
    Egg lecithin
    Glycerol
    SWFI
    NaOH for pH
    polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.
    Vial 2: mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.
    Soya oil
    Egg lecithin
    Glycerol
    SWFI
    NaOH for pH
    Aluminum≤ 70 mcg/L (vials 1+2) Not reported ≤ 30 mcg/L (Vials 1 + 2). Not reported
    IndicationFor prevention of vitamin deficiency in adults and
    children aged 11 and older receiving parenteral nutrition
    Indicated in adult patients and children from 11 years of age as a supplement in intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A, D2, E and K1. For the prevention of vitamin deficiency in
    pediatric patients up to 11 years of age receiving parenteral nutrition
    Indicated in infants and children up to 11 years of age as a supplement in intravenous nutrition to meet the daily requirements of the fat-soluble vitamins A, D2, E and K1.
    Dose10 mL 10 mL <1 kg: 1.5 mL
    1 to <3 kg: 3.25 mL
    ≥3 kg: 5 mL
    Preterm and infants below 2.5 kg: 4 mL/kg/d
    Infants and children >2.5 kg and up to 11 years: 10 mL/d
    ContraindicationsAn existing hypervitaminosis, or
    A history of hypersensitivity due to any vitamins or excipients contained in this
    formulation.
    Egg, soy, peanut allergy, hypersensitivity to ingredient/excipient An existing hypervitaminosis, or A history of hypersensitivity to any vitamins or excipients contained in this
    formulation.
    Egg, soy, peanut allergy, hypersensitivity to ingredient/excipient

    The following 2 tables compare the content of Infuvite, Vitalipid N and ASPEN Vitamin Recommendations for adult and pediatric patients.

    Daily Adult ASPEN Guideline Recommendations for Multivitamins and amount in Vitalipid N Adult and Infuvite Adult Products
    Adult: Guideline Recommendations7Vitalipid N Adult2,3
    (10 mL dose)
    Infuvite Adult1
    (10 mL dose)
    Thiamine (B1)6 mg 6 mg
    Riboflavin (B2)3.6 mg 3.6 mg
    Niacin (B3)40 mg 40 mg
    Pantothenic Acid (B5)5 mg 15 mg
    Pyridoxine (B6)6 mg 6 mg
    Biotin60 mcg 60 mcg
    Folate600 mcg 600 mcg
    Cyanocobalamin (B12)5 mcg 5 mcg
    Vitamin C (ascorbic acid)200 mg 200 mg
    Vitamin A990 mcg (3300 IU) 990 mcg (3300 IU) 3300 IU (1 mg)
    Vitamin D5 mcg (200 IU) 5 mcg (200 IU) 200 IU (5 mcg)
    Vitamin E10 mg (10 IU) 9.1 mg (10 IU) 10 IU (10 mg)
    Vitamin K150 mcg 150 mcg 150 mcg
    Daily Pediatric ASPEN Guideline Recommendations for Parenteral Multivitamins and amount in Vitalipid N Infant and Infuvite Pediatric Products
    Preterm Neonates: Guideline RecommendationsInfants: Guideline Recommendations7Children: Guideline Recommendations7Vitalipid N Infant5,6
    (10 mL)
    Infuvite Pediatric (4 mL+ 1 mL)4
    Pediatric Dosing
    Amounts/kg/d

    Amounts/kg/d

    Amounts/d
    Preterm and <2.5 kg: 4 mL/kg
    >2.5 kg to 11 years: 10 mL
    < 1 kg: 1.5 mL
    1 kg - <3 kg: 3.25 mL
    ≥ 3 kg: 5 mL
    Thiamine (B1), mg200–350 mcg 0.35 -0.5 1.2 1.2 mg
    Riboflavin (B2, mg)50–200 mcg 0.15 – 0.2 1.4 1.4 mg
    Niacin (B3), mg4–6.8 4 – 6.8 17 17 mg
    Pantothenic Acid (B5), mg1–2 1 – 2 5 5 mg
    Pyridoxine (B6), mg150–200 mcg 0.15 – 0.2 1 1 mg
    Biotin , mg5-8 mcg 5 – 8 20 20 mcg
    Folate, mcg56 mcg 56 140 140 mcg
    Cyanocobalamin (B12), mcg0.3 0.3 1 1 mcg
    Vitamin C (ascorbic acid), mg15-25 15 – 25 80 80 mg
    Vitamin A , mcg (IU)700-1500 IU 150-300 (500 – 1000 IU) 150 (500 IU) 690 (2300 IU) 700 mcg (2300 IU)
    Vitamin D, mcg (IU)40-160 IU 0.8 (32 IU) 10 (400 IU) 10 mcg (400 IU) 10 mcg (400 IU)
    Vitamin E , mg2.8-3.5 IU 2.8 – 3.5 7 6.4 mg (7 IU) 7 mg (7 IU)
    Vitamin K1 , mcg10 10 200 200 mcg 200 mcg
    Refer to the Vitalipid N package insert for full prescribing information

    REPORTING ADVERSE EVENTS

    To report adverse events experienced with the use of this product, call Fresenius Kabi USA Vigilance at 1-800-551-7176, Monday – Friday, between the hours of 8 a.m. and 5 p.m. (CST), or e-mail adverse.events.USA@fresenius-kabi.com

    To report a product complaint with the use of this product, call (800) 551- 7176 or e-mail productcomplaint.USA@fresenius-kabi.com.

    Fresenius Kabi USA CONTACT NUMBERS: Please use the following contact numbers as appropriate:

    Reason To CallDepartmentNumber
    ADE Reporting Vigilance Department 1-800-551-7176
    Clinical/Technical Info. Or Product Complaint Medical Affairs Department
    Product Availability & Ordering Customer Service Department 1-888-386-1300

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    • Complete and submit the report Online: www.fda.gov/medwatch/report.htm
    • Regular Mail or Fax: Download form www.fda.gov/medwatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178).

    Sincerely,

    Figure

    Gordon S. Sacks, PharmD, BCNSP, FASPEN, FCCP
    Senior Director, Medical Affairs
    Fresenius Kabi USA, LLC

    Vitalipid N and Vitlipid N, Infuvite Pediatric and Infuvite Adult Product Labels
    ProductShipper labelBox LabelAmpule/Vial labelAmpule/Vial picture
    Vitalipid N InfantFigure
Figure
Figure
Figure
    Vitlipid N InfantFigure
    Figure

    Figure
    Not available
    Infuvite Pediatric
    (Baxter Healthcare)
    Not available
    Figure
    Not available
    Figure
    Vitlipid N Adult
    Figure

    Figure

    Figure
    Not available
    Infuvite Adult (Baxter Healthcare)Not available
    Figure

    Figure

    References:

    1. Infuvite Adult. Prescribing Information. Baxter Healthcare Corporation. Deerfield IL. October 2016.
    2. Vitalipid N Adult Summary of Product Characteristics. Fresenius Kabi 2008
    3. Vitalipid N Adult Prescribing Information, Fresenius Kabi AB. Uppsala, Sweden
    4. Infuvite Pediatric. Prescribing Information. Baxter Healthcare Corporation. Deerfield IL. October 2016.
    5. Vitalipid N Infant Prescribing Information, Fresenius Kabi AB. Uppsala, Sweden
    6. Vitalipid N Infant Summary of Product Characteristics. Fresenius Kabi 2008
    7. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. Position Paper: Recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-491.
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID® N Infant 10 mL Ampule Label

    Vitalipid® N Infant 10 ml

    Concentrate for emulsion for infusion

    For intravenous infusion

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID® N Infant 10 mL Ampule Label
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID® N Infant 10 mL Ampule Carton Panel

    Vitalipid® N Infant

    Concentrate for emulsion for infusion

    For intravenous infusion

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID™ N Infant 10 mL Ampule Label

    Vitalipid N Infant 10 ml

    Concentrate for solution for infusion, emulsion

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID™ N Infant 10 mL Ampule Label
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID™ N Infant 10 mL Ampule Carton Panel

    Vitalipid N Infant

    Concentrate for solution for infusion

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID™ N Infant 10 mL Ampule Carton Panel
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID® N Adult 10 mL Ampule Label

    Vitalipid® N Adult 10 ml

    Concentrate for emulsion for infusion

    For intravenous infusion

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID
  • PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID® N Adult 10 mL Ampule Carton Panel

    Vitalipid® N Adult

    Concentrate for emulsion for infusion

    For intravenous infusion

    PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – VITALIPID
  • INGREDIENTS AND APPEARANCE
    VITALIPID N 
    vitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione emulsion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:65219-337
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VITAMIN A PALMITATE (UNII: 1D1K0N0VVC) (VITAMIN A - UNII:81G40H8B0T) VITAMIN A230 [iU]  in 1 mL
    Ergocalciferol (UNII: VS041H42XC) (Ergocalciferol - UNII:VS041H42XC) Ergocalciferol40 [iU]  in 1 mL
    .ALPHA.-TOCOPHEROL, DL- (UNII: 7QWA1RIO01) (.ALPHA.-TOCOPHEROL, DL- - UNII:7QWA1RIO01) .ALPHA.-TOCOPHEROL, DL-0.7 [iU]  in 1 mL
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE20 ug  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    EGG PHOSPHOLIPIDS (UNII: 1Z74184RGV)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    SOYBEAN OIL (UNII: 241ATL177A)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:65219-337-6210 in 1 CARTON08/18/2023
    1NDC:65219-337-1010 mL in 1 AMPULE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved drug for use in drug shortage08/18/2023
    VITALIPID N 
    vitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione emulsion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:65219-339
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VITAMIN A PALMITATE (UNII: 1D1K0N0VVC) (VITAMIN A - UNII:81G40H8B0T) VITAMIN A230 [iU]  in 1 mL
    Ergocalciferol (UNII: VS041H42XC) (Ergocalciferol - UNII:VS041H42XC) Ergocalciferol40 [iU]  in 1 mL
    .ALPHA.-TOCOPHEROL, DL- (UNII: 7QWA1RIO01) (.ALPHA.-TOCOPHEROL, DL- - UNII:7QWA1RIO01) .ALPHA.-TOCOPHEROL, DL-0.7 [iU]  in 1 mL
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE20 ug  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    EGG PHOSPHOLIPIDS (UNII: 1Z74184RGV)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    SOYBEAN OIL (UNII: 241ATL177A)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:65219-339-6410 in 1 CARTON08/18/2023
    1NDC:65219-339-1010 mL in 1 AMPULE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved drug for use in drug shortage08/18/2023
    VITALIPID N 
    vitamin a palmitate, ergocalciferol, .alpha.-tocopherol, dl-, phytonadione emulsion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:65219-335
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VITAMIN A PALMITATE (UNII: 1D1K0N0VVC) (VITAMIN A - UNII:81G40H8B0T) VITAMIN A330 [iU]  in 1 mL
    Ergocalciferol (UNII: VS041H42XC) (Ergocalciferol - UNII:VS041H42XC) Ergocalciferol20 [iU]  in 1 mL
    .ALPHA.-TOCOPHEROL, DL- (UNII: 7QWA1RIO01) (.ALPHA.-TOCOPHEROL, DL- - UNII:7QWA1RIO01) .ALPHA.-TOCOPHEROL, DL-1 [iU]  in 1 mL
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE15 ug  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    EGG PHOSPHOLIPIDS (UNII: 1Z74184RGV)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    SOYBEAN OIL (UNII: 241ATL177A)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:65219-335-8210 in 1 CARTON08/18/2023
    1NDC:65219-335-1010 mL in 1 AMPULE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Unapproved drug for use in drug shortage08/18/2023
    Labeler - Fresenius Kabi USA, LLC (013547657)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fresenius Kabi AB559785113ANALYSIS(65219-337, 65219-339, 65219-335) , API MANUFACTURE(65219-337, 65219-339, 65219-335) , MANUFACTURE(65219-337, 65219-339, 65219-335)